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Abstract
A quantitative PCR method was established to quantify human bocavirus (HBoV)
genomic copies in clinical specimens from children with lower respiratory tract
infections (LRTI) in China. A total of 257 respiratory tract specimens were tested, and
7 (2.7%) of these (all sputum samples) were positive, with genomic copies that ranged
from 8.0 × 103 to 8.0 × 109 in the samples. The main clinical symptom of patients who
were positive for HBoV DNA was a pneumonia-like syndrome represented by high
fever and cough. Our results suggest that HBoV may be an important etiological agent
of LRTI in children in China.
Finding
Virus infection is the major cause of lower respiratory tract
infections (LRTI) in children worldwide, and the most
important viral agent is arguably respiratory syncytial
virus (RSV) [1]. Others viruses such as influenza viruses,
parainfluenza viruses, adenoviruses, rhinoviruses, coro-
naviruses, and human metapneumovirus are also fre-
quently reported to cause LRTI [2-5]. Human bocavirus
(HBoV) was first cloned from pooled human respiratory
tract samples collected in Sweden, and was provisionally
classified into the genus Bocavirus  based on sequence
comparisons [6]. HBoV has been reported worldwide to
be present in between 1.5% to 11.3% of respiratory sam-
ples tested from individuals with acute respiratory illness
[7-10], and it appears to be associated with LTRI [11-13].
To date, there have been no studies reporting the detec-
tion of HBoV DNA in children with LRTI from China.
Currently, detection of HBoV in children with LRTI
mainly relies on DNA amplification by regular PCR.
Because these assays are not quantitative, positive results
are hard to interpret. Recently, a reliable quantitative PCR
(Q-PCR) method has been developed to detect HBoV
genomic copies in clinical samples, and this has demon-
strated a presence of HBoV DNA in children with pneu-
monia-like symptoms in Thailand [14]. In this study, we
used a Q-PCR with the amplicon targeted to the NS cod-
ing region of HBoV to detect the presence of HBoV DNA
in children with respiratory tract infection in China. Our
results suggest that HBoV may be an important etiological
agent of LRTI in children in China.
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A total of 257 specimens were collected from December,
2005 to February, 2006 from infants or children with LRTI
hospitalized in Wenling First Hospital, Zhejiang Province,
China. The specimens included throat swab, nasopharyn-
geal aspirate, sputum and aspirated sputum, together with
blood samples, on the day of hospitalization. All the
blood samples tested negative for antibodies directed
against influenza virus A and B, respiratory syncytial virus
(RSV), parainfluenza virus and adenovirus by commer-
cially available ELISA kits. All these clinical samples were
taken after informed consent was obtained from parents
or other legal guardians,
DNA extraction from clinical specimens was performed as
follows. Throat swab and nasopharyngeal aspirates were
diluted in 2 ml of PBS, and were centrifuged at 12,000
rpm at 4°C for 10 min. The pellets were resuspended in
200 µl PBS. The sputum and aspirated sputum specimens
were digested with 3 volumes of 4% NaOH, and were cen-
trifuged at 8,000 rpm at 4°C for 5 min. Pellets were fur-
ther washed with PBS and resuspended in a final volume
of 200 µl PBS. All these resuspended pellets were extracted
DNA using QIAamp blood mini kit (QIAGEN). A plasmid
(pskHBoV) containing the HBoV sequence (nts 1-5299)
was synthesized by extension of PCR fragments with
primers designed based on the ST2 sequence of HBoV
[Genbank: DQ000496], and this was subsequently
inserted into pBluescript vector (Stratagene). This plasmid
was used as a control (1 genomic copy = 5 × 10-12 µg) to
establish the standard curve for absolute quantification
using TaqMan technology with an Applied Biosystems
7500 system (Foster City, Calif.) as a quantitative PCR
method [15,16]. The amplicon and the TaqMan probe for
this HBoV specific quantitative PCR were designed by
Primer Express 2.0.0 software(Applied Biosystems) in the
conserved regions of the NS coding region among HBoV
genome sequences deposited in GenBank. Their
sequences are as follows: forward primer, 5' AGC TTT TGT
TGA TTC AAG GCT ATA ATC (HBoV nts 1417 to 1444);
reverse primer, 5' TGT TTC CCG AAT TGT TTG TTC A'3
(HBoV nts 1500 to 1480); and the probe, 5'FAM-TCT
AGC CGT TGG TCA CGC CCT GTG-TAMRA3' (HBoV nts
1446 to 1469). TaqMan universal PCR master mix
(Applied Biosystems) was used for amplification with the
standard protocol. 5 µl of extracted DNA was used in a
reaction volume of 25 µl.
HBoV DNA was detected in sputum and aspirated spu-
tum. A total of 7 (2.7%) of 257 specimens tested were pos-
itive for HBoV by Q-PCR (Table 1). All 7 positive samples
were either sputum or aspirated sputum, indicating a sig-
nificant presence of HBoV DNA in lower respiratory tract.
There was no significant age difference in detection of
HBoV genome in specimens. These positive samples con-
tained a substantial titer of virus with genomic copies
ranged from 4.0 × 103 to 4.0 × 109/ml in the original col-
lected sample (2 ml), suggesting active replication of virus
in the lower respiratory tract. The main clinical symptom
of patients who were positive for HBoV DNA was a pneu-
monia-like syndrome represented by high fever (>39°C)
and cough.
The rate of detection that we observed in this population
was lower than the average of these previously reported
[7-10]. This might reflect either a truly lower frequency of
HBoV infection the Zhejiang Province of China, or, alter-
natively, variations in the amplicon within these Chinese
HBoV isolates. In addition, lower copy numbers of viral
genomes were not detected in our assay, perhaps because
of limitations in the extraction of DNA from specimens or
inhibitors of the Q-PCR in the clinical specimens. Further
investigation with different paired primers and probes to
quantify the HBoV genome in clinical samples are under
way for probing the etiology of HBoV in LTRI in children,
using, in addition, normal controls. Nevertheless, this
quantitative PCR method provides a reliable means to
screen samples with high titers of genomic copies for virus
isolation and to begin to address the relationship between
HBoV and LRTI in children in China.
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Table 1: Clinical characteristics of 7 patients positive for HBoV DNA by Q-PCR
No. specimens Type of samples Sex Age Symptom Genomic copies (gc/ml)* Clinical Diagnosis
WL102 Aspirated sputum F 13 mo Fever with cough for 10 day 1.46 × 107 Pneumonia
WL108 Aspirated sputum F 1 yr Fever with cough for 5 day, seizure once 3.95 × 109 Pneumonia
WL109 Sputum F 7 yr Fever for 2 days, 4.01 × 103 Bronchiolitis
WL160 Aspirated sputum M 7 mo Fever for 5 days and cough for 3 days 4.51 × 103 Bronchitis
WL221 Aspirated sputum M 2 yr Fever and cough for 2 days 6.95 × 105 Bronchiolitis
WL223 Sputum F 3 yr Fever for 3 days 6.94 × 105 Bronchiolitis
WL226 Sputum M 3 yr Fever and cough for 5 days 5.45 × 104 Bronchitis
*The number of genomic copies was converted to per ml in the original collected sample (2 ml).Publish with BioMed Central    and   every 
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